Vimarsana
Biggest News Aggregation in the World

Kellgren Lawrence News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kellgren Lawrence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kellgren Lawrence Today - Breaking & Trending Today

New Projections for the Global Burden of Osteoarthritis Through 2050 - Vimarsana News

New Projections for the Global Burden of Osteoarthritis Through 2050

Through a series of regression analyses, researchers projected the ever-increasing global burden of osteoarthritis (OA) until 2050.

Source: ajmc.com
Corticosteroid Injections Appear to Worsen Knee Osteoarthritis - Vimarsana News

Corticosteroid Injections Appear to Worsen Knee Osteoarthritis

Corticosteroid injections seem to be associated with progression of knee osteoarthritis.

RSNA: Corticosteroid Injections Appear to Worsen Knee Osteoarthritis - Vimarsana News

RSNA: Corticosteroid Injections Appear to Worsen Knee Osteoarthritis

WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- Corticosteroid injections seem to be associated with progression of knee osteoarthritis (OA), according to two studies presented at the annual meeting of the Radiological Society of North America, held from Nov. 27 to Dec. 1 in Chicago. Upasana Upadhyay Bharadwaj, M.D., from the University of California in San

RSNA: Corticosteroid Injections Appear to Worsen Knee Osteoarthritis - Vimarsana News

RSNA: Corticosteroid Injections Appear to Worsen Knee Osteoarthritis

Corticosteroids linked to progression of knee OA based on whole-organ magnetic resonance imaging scores, KL grade.

Source: empr.com
Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial - Vimarsana News

Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial

KEY HIGHLIGHTS Primary endpoint relating to synovial fluid biomarkers achieved and positive top-line results reported for the PARA_OA_008 phase 2 clinical...